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Dense deposit disease (DDD) is a rare disorder characterized by 
the deposition of abnormal electron-dense material within the 
glomerular basement membrane of the kidneys. The diagnosis is 
made in most patients between 5 and 15 years of age, and within 
10 years, approximately half of the affected patients progress to 
end-stage renal disease. We report a rare case of regressive DDD 
without C3 deposition after steroid therapy in an 11-year-old boy. The 
patient presented with edema, gross hematuria, and nephrotic-range 
proteinuria. Laboratory testing revealed a serum creatinine level of 1.17 
mg/dL, albumin level of 2.3 g/dL, and serum C3 level of 125 mg/dL 
(range 90-180 mg/dL). The results of the renal biopsy were consistent 
with DDD without C3 deposition. After 6 weeks of steroid therapy, 
the nephrotic syndrome completely resolved. The follow-up renal 
biopsy showed a significant reduction in mesangial proliferation and 
disappearance of electron-dense deposits in the GBM. 
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Introduction 
Membranoproliferative glomerulonephritis (MPGN) is a 
chronic progressive renal disease that is diagnosed by renal 
histological features. On the basis of immunopathology and 
ultrastructure analysis of the kidney and of the glomerulus, three 
subtypes are recognized. MPGN types I and III are variants of 
immune complex-mediated disease; MPGN II, which is also 
known as dense deposit disease (DDD), by contrast, has no known 
association with immune complexes. Because recent studies have 
indicated that the light microscopy pattern in most patients is 
not membranoproliferative, the recent trend is to consider DDD 
a distinct entity, rather than a variant of MPGN
1). MPGN II 
is rare, and it accounts for less than 20% of all cases of MPGN 
in children
2). Its morphologic hallmark is the presence of dense 
deposits within the glomerular basement membrane (GBM) as 
observed by electron microscopy. 
MPGN II has a poor prognosis and, with few exceptions, there is 
usually no change in the dense deposits on follow-up
2, 3). Although 
there is no universally effective treatment for MPGN II, some 
reports
4, 5) suggest that prednisone therapy can reduce proteinuria 
and prolong renal survival. 
We report the case of a child with atypical DDD who achieved 
complete remission, clinical and morphological, after steroid 
therapy.
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Case report
An 11-year-old boy presented with gross hematuria, proteinuria 
and generalized edema for five days. There had been no systemic 
illness, rash or joint pain. His past and family histories were not 
remarkable for renal disease. Laboratory data included a white 
blood cell count of 7,000/mm
3 with a normal differential count, 
hemoglobin 11.0 g/dL, and a platelet count of 337,000/mm
3. 
The total serum protein was 4.7 g/dL, with a serum albumin 
concentration of 2.3 g/dL. The serum creatinine level was 1.17 
mg/dL, cholesterol 525 mg/dL and triglycerides 153 mg/dL. The 
glomerular filteration rate was 66.3 ml/min/1.73 m
2. Urinalysis 
showed hematuria and proteinuria (3+), and the 24 hour urinary 
protein excretion was 2,625 mg. The serum C3 level was 125 
mg/dL (range 90-180 mg/dL) and the C4 level was 33.6 mg/dL 
(range 10-40 mg/dL). The anti-nuclear antibodies, anti-neutrophil 
cytoplasm antibodies, anti-hepatitis B virus, Epstein-Barr virus, 
cytomegalovirus antibodies, and anti-streptolysin O titer were all 
negative.
The patient underwent a renal biopsy on the fourth hospital 
day. On light microscopy, the biopsy showed 43 glomeruli. Some 
glomeruli had mesangial hypercellularity or lobular accentuation 
(Fig. 1). The glomerular capillary walls were thickened and 
showed a segmental double contour. In addition, mild interstitial 
fibrosis and tubular atrophy were present. The ultrastructural 
examination showed wide foot process effacement, irregularly 
thickened glomerular basement membrane (GBM), and electron-
dense deposits in the lamina densa (Fig. 2). Immunofluorescence 
examination was negative for immunoglobulin (Ig) G, Ig A, Ig 
M and C3 deposition. Even though the serum C3 level was not 
low and there was no C3 deposition along the capillary walls, the 
pathology was consistent with DDD. 
Daily prednisolone therapy (60 mg/m
2/day) was started with 
dipyridamole. After 28 days of daily prednisone therapy, the 
prednisolone was reduced to alternate day treatment (40 mg/m
2/
day) and then gradually weaned. Six weeks after steroid therapy, 
the nephrotic syndrome was in remission with no further relapse. 
However, he continued to have microscopic hematuria for 16 
Fig. 1. Light microscopic features of dense deposit disease. A) Lobular configuration of the glomerular 
tuft due to expansion of the endocapillary zones by cells and matrix (periodic acid-Schiff stain, ×400) B) 
Mesangial hypercellularity accompanied by a mild increase in mesangial matrix (periodic acid-Schiff stain, 
×400).
Fig. 2. Electron microscopic features of dense deposit disease: (A) Intramembranous electron-dense 
deposits thicken the glomerular basement membranes (×4000); (B) Discontinuous intramembranous 
rounded aggregates of electron-dense material (×4000).768      MS Kim, et al. • A case of dense deposit disease 
months after disease onset. At 18 months after onset of the 
glomerulonephritis, a follow-up renal biopsy was performed. The 
second renal biopsy showed significant reduction of mesangial 
proliferation with mild mesangial expansion and disappearance of 
the electron-dense deposits in the GBM (Fig. 3). In contrast to the 
first biopsy, mild Ig M staining (1+) was detected in the mesangium. 
Currently, the patient has been monitored for seven years; he 
remains well, and has no urinary abnormalities. 
Discussion 
This is a very rare case of atypical DDD that showed complete 
resolution of the dense deposits after steroid therapy. The natural 
history of idiopathic DDD was recorded in this 11 year old boy that 
followed for seven years and showed complete resolution of DDD 
after high dose prednisolone therapy. The first reported case of 
MPGN II was described in 1962
6). However, the natural history of 
MPGN II remains unclear.
Clinical manifestations at diagnosis, such as the nephrotic 
syndrome, hypertension, persistent hypocomplementemia and 
the biopsy findings of glomerular crescents or tubular atrophy 
have been previously cited as indicators of a poor outcome
2, 3). 
Recently, Nasr et al
7) reported that an older age and higher serum 
creatinine at biopsy are predictors of a poor prognosis in patients 
with DDD. Taking into account the prior reports of predictive 
factors, our patient had a good prognosis because of the young age, 
normal blood pressure, normal C3 level, and absence of glomerular 
crescents. In addition, absence of C3 deposition on GBM may be a 
predictable marker for good prognosis as in our case. 
Distinct features of MPGN II include the complement profile 
and the frequent presence of the nephritic factor (NF). The profile 
usually includes C3 levels that are markedly depressed with normal 
or near normal levels of other components
8). In more than 50% of 
patients, the serum C3NF persists throughout the disease course
9). 
C3NF is always associated with clinical evidence of complement 
activation such as a reduction in CH50 and a decrease in C3. 
However, the relationship among C3NF, C3 levels and prognosis 
is unclear. Some groups report no correlation between C3 levels 
and clinical course
7, 10), whereas other groups have found persistent 
hypocomplementemia indicative of a poor prognosis
3, 11). Klein M 
et al.
12) showed that the DDD patients with normal amounts of C3 
and factor B, and low levels of C3NF activity had a benign course. 
The level of C3 in our patient was not decreased throughout the 
course of the disease over the seven years of follow up, but factor B 
and C3NF were not checked.
The dense intramembranous deposits in the GBM are the 
pathognomonic feature of MPGN II, and are distributed in a 
segmental, discontinuous, or diffuse pattern in the lamina densa of 
the GBM. The GBM is not a static structure, and the dense deposits 
represent a biochemically altered BM substance
13). Tornroth and 
Skrifvars
14) suggested a slow turnover of GBM with removal of 
deposit material on the endothelial side of the GBM in patients 
with gold-induced membranous nephropathy. Spontaneous 
remissions of MPGN II are uncommon, and electron dense 
deposits usually are still present on follow-up renal biopsies. To date, 
spontaneous improvement, clinical and morphological, has been 
reported in only a few cases of MPGN II in children
4, 15). McEnery 
and McAdams
4) reported that six children with MPGN II showed 
significant reduction in pathological changes, and complete 
resolution of the dense deposits were observed in two patients that 
had normal C3 levels. The improvement of the clinical status with 
steroid therapy, normal serum C3 level and no C3 deposition on 
GBM, in our patient, might predict the possibility of changes in 
glomerular morphology including resolution of the dense deposits 
on follow-renal biopsy. In this patient, significant reduction of 
mesangial proliferation and complete regression of the dense 
Fig. 3. Dense deposit disease after treatment. A) A second biopsy 18 months after treatment shows 
striking improvement in the severity of the glomerulonephritis with regression of the proliferation (periodic 
acid-Schiff stain, ×400). B) Electron micrograph shows focal foot process effacement, segmental irregular 
thickening of glomerular basement membrane, and no electron dense deposits (×4,000). Korean J Pediatr 2010;53(7):766-769 • DOI: 10.3345/kjp.2010.53.7.766    769
deposits was observed 18 months after disease onset. The present 
observations suggest that the renal pathology associated with DDD 
is fundamentally transient and that resolution, if it occurs, does so 
slowly over several years.
Various treatment modalities, including immunosuppression 
with corticosteroids, cytotoxic drugs and cyclosporin A, 
anticoagulants and antiplatelet therapies are used for DDD with 
varying degrees of success
3). The efficacy of steroid therapy is 
controversial. McEnery and McAdams
4) reported improvement in 
glomerular morphology and a good clinical outcome with long-
term alternate-day prednisone therapy. Our patient showed clinical 
remission within six weeks of steroid therapy. Whether clinical and 
morphological regression were due to steroid therapy is difficult to 
confirm. However, steroid therapy may promote clinical remission 
and spontaneous removal of dense deposit by modification or 
elimination of the nephritic elements associated with this disease. 
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